MARKET

BCDA

BCDA

BioCardia
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.550
+0.110
+4.51%
Closed 19:59 12/03 EST
OPEN
2.490
PREV CLOSE
2.440
HIGH
2.600
LOW
2.450
VOLUME
183.88K
TURNOVER
--
52 WEEK HIGH
6.75
52 WEEK LOW
1.910
MARKET CAP
31.69M
P/E (TTM)
-1.3033
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BioCardia Reports Published Study Showing Helix Biotherapeutic Delivery System Used in CardiAMP Phase III Heart Failure Trial Has Fewest Adverse Events Among Competitive Delivery Systems
GlobeNewswire · 2d ago
BioCardia Reports Third Quarter 2020 Financial Results and Business Highlights
BioCardia(R), Inc. [NASDAQ: BCDA], a leader in the development of autologous and allogenic cell therapies, today reported financial results and business highlights for the third quarter of 2020 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2020 with the Securities and Exchange Commission on November 10, 2020.
GlobeNewswire · 11/10 12:00
The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 29)
Benzinga · 10/30 12:09
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
Published Peer-reviewed Initial Data from BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function
Paper Published in International Journal of Cardiology Demonstrates Safety and Tolerability While Showing Functional Improvement at Six Months SAN CARLOS, Calif., Oct. 26, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA](“BioCardia” or the “Company”), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the publication of data from the Company’s initial open-label roll-in cohort that served as the precursor for the Company’s ongoing CardiAMP™ Heart Failure (HF) Phase 3 clinical trial. Published in the International Journal of Cardiology, the study data shows that CardiAMP is a well-tolerated treatment in heart failure patients and demonstrated improved distance in six-minute exercise testing at six months and a trend toward improvement at one year. This 10-patient cohort was the feasibility test for the currently enrolling CardiAMP HF Phase 3 clinical trial.The study, entitled “Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort,” followed 10 patients with chronic post-heart attack heart failure (NYHA class II and III) who underwent a 5 ml bone marrow aspiration to determine cell potency using the patented CardiAMP cell potency assay followed by CardiAMP cell therapy, consisting of bone marrow mononuclear cell (BM MNC) enrichment and transendocardial injection of 200 million BM MNCs, at a subsequent single point-of-care visit. The study followed those subjects for 12 months and showed no serious adverse events related to bone marrow or cell delivery. Importantly, improvement at six months was observed in Six Minute Walk distance (+47.8 meters, p=0.01) and trended to improvement at 12 months (+46.4 meters, p=0.06). Echocardiographic data substantiated the improved performance of patients, as better contractility was seen of the heart.“These results surpassed what we saw in our Phase 2 trial in similar NYHA Class I, II, and III ischemic heart failure patients. Utilizing our cell potency assay is an important component of the CardiAMP treatment process, as it is the potency of the patients’ own cells that facilitates the regeneration and, therefore, the therapy. The results for these 10 patients are a meaningful marker for the heart failure community as a whole, and we believe it bodes well for our larger trial, for which these first patients laid the groundwork,” said BioCardia Chief Medical Officer Eric Duckers, M.D., Ph.D. “Our current CardiAMP HF trial is currently enrolling, and we anticipate full enrollment as early as the fourth quarter of 2021. In the meantime, we expect to receive the results from our data and safety monitoring board (DSMB) review by December 15, 2020.”The published paper also reported 12-month trends toward improvement in a variety of cardiac functions, including left ventricular ejection fraction and recruitment of previously akinetic left ventricular wall segments. The 10-patient cohort also displayed trends toward improvement of NYHA heart failure functional class and overall quality of life. The International Journal of Cardiology article is currently available online here and is expected to be available in print in the coming weeks.About BioCardia BioCardia, Inc., headquartered in San Carlos, California, is developing autologous and allogenic cell-based therapies to treat cardiovascular disease. CardiAMP™ and CardiALLO™ cell therapies are the Company’s biotherapeutic product candidates in clinical development. The Company has also developed a portfolio of approved enabling products that optimize delivery of its cell therapies.Forward Looking Statements  This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, the intended outcomes of and enrollment in our trials, the efficacy and safety of our products and therapies, and statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations. Such risks and uncertainties include, among others, the inherent uncertainties associated with developing new products or technologies, obtaining regulatory approvals, and the ability to raise the additional funding needed to continue to pursue BioCardia’s product development plans. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements. We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate.  Additional factors that could materially affect actual results can be found in our documents filed with the SEC, including our recent filings on Form 8-K, Form 10-K and Form 10-Q, particularly any statements under the caption entitled “Risk Factors” therein.” BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Media Contact: Michelle McAdam, Chronic Communications, Inc. michelle@chronic-comm.com (310) 902-1274Investor Contact: David McClung, Chief Financial Officer Investors@BioCardia.com (650) 226-0120
GlobeNewswire · 10/26 12:30
BioCardia Highlights Published Peer-Reviewed Initial Data From Biocardia Pivotal Phase 3 Clinical Trial Of Cardiamp
Paper Published in International Journal of Cardiology Demonstrates Safety and Tolerability While Showing Functional Improvement at Six Months   SAN CARLOS, Calif.,
Benzinga · 10/26 11:37
Published Peer-reviewed Initial Data from BioCardia Pivotal Phase 3 Clinical Trial of CardiAMP Demonstrates Improvement in Heart Failure Patients Measured by Exercise Outcomes and Cardiac Function
Paper Published in International Journal of Cardiology Demonstrates Safety and Tolerability While Showing Functional Improvement at Six Months
GlobeNewswire · 10/26 11:30
Read This Before Selling BioCardia, Inc. (NASDAQ:BCDA) Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Simply Wall St. · 10/20 12:05
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BCDA. Analyze the recent business situations of BioCardia through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BCDA stock price target is 12.88 with a high estimate of 19.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 1.21M
% Owned: 9.75%
Shares Outstanding: 12.43M
TypeInstitutionsShares
Increased
3
2.88K
New
5
-106.57K
Decreased
1
152
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.41%
Pharmaceuticals & Medical Research
+0.49%
Key Executives
Chairman/Independent Director
Simon Stertzer
President/Chief Executive Officer/Director
Peter Altman
Chief Financial Officer
David McClung
Vice President - Operations
Phil Pesta
Other
Henricus Duckers
Independent Director
Jim Allen
Independent Director
Andrew Blank
Independent Director
Fernando Fernandez
Independent Director
Richard Krasno
Independent Director
Jay Moyes
Independent Director
Richard Pfenniger
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About BCDA
BioCardia, Inc. is a clinical-stage regenerative medicine company engaged in developing therapeutics for cardiovascular diseases. The Company's therapeutic portfolio consists of the CardiAMP and CardiALLO cell therapies. The Company's lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP) and focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company's CardiALLO Cell Therapy System (CardiALLO), is an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. The Company’s products also include Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths Products.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of BioCardia Inc stock information, including NASDAQ:BCDA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCDA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCDA stock methods without spending real money on the virtual paper trading platform.